HIV vaccine - Progenics

Drug Profile

HIV vaccine - Progenics

Alternative Names: HIV gp140 vaccine - Progenics; ProVax

Latest Information Update: 23 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aaron Diamond AIDS Research Center; Progenics Pharmaceuticals; Weill Cornell Medical College
  • Developer Progenics Pharmaceuticals
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Mar 2012 Discontinued - Preclinical for HIV infections in USA (Parenteral)
  • 23 Nov 2011 HIV vaccine - Progenics is available for licensing as of 09 Nov 2011. http://www.progenics.com
  • 12 Apr 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top